Articles

Videos

Podcasts

Clinical

Go-Out is a natural supplement that treats high uric acid levels.

Daily OTC Pearl: Go-Out 

Febuxostat) Uloric is a xanthine oxidase inhibitor indicated for the chronic management of hyperuricemia in patients with gout.

Daily Medication Pearl: Febuxostat (Uloric)

ClearoGout aids in the prevention of gout attacks.

Daily OTC Pearl: ClearoGout

Patients with gout have a 4 times greater risk of a cardiovascular episode within the 60 days following their flare up.

Study: Gout Flare Ups Can Lead to Four-Times Higher Risk of Heart Attack, Stroke 

Novadoz Pharmaceuticals, who markets the product, has commenced shipping of the drug, available in bottles of 30 tablets.

FDA Approves Generic Tablets for Treatment of Gout

Febuxostat was FDA-approved in 2009 to treat gout in adults.

FDA Adds Boxed Warning for Febuxostat

The statement is intended to serve as a discussion guide for the risk factors, diagnosis, treatment and prevention of the disease.

Joint Clinical Consensus Statement Addresses Gout Treatment

Nonsteroidal anti-inflammatory drugs should be used as the first line treatment for acute gout.

New Clinical Consensus Statement Designed to Address Gout Treatment

The FDA has approved Duzallo (lesinurad and allopurinol; Ironwood Pharmaceuticals, Inc) for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid (sUA) levels with a medically appropriate daily dose of allopurinol alone.

Clinical Pharmacology Update: Duzallo

Febuxostat (Uloric) could escalate heart-related and all-cause mortality.